Home » Stocks » GERN

Geron Corporation (GERN)

Stock Price: $1.73 USD 0.06 (3.59%)
Updated Jan 22, 2021 4:00 PM EST - Market closed
After-hours: $1.70 -0.03 (-1.73%) Jan 22, 7:56 PM
Market Cap 537.12M
Revenue (ttm) 374,000
Net Income (ttm) -80.90M
Shares Out 318.80M
EPS (ttm) -0.34
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 22
Last Price $1.73
Previous Close $1.67
Change ($) 0.06
Change (%) 3.59%
Day's Open 1.65
Day's Range 1.65 - 1.74
Day's Volume 2,085,806
52-Week Range 0.89 - 2.19

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 3 days ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 120,000 shares of Geron common...

Business Wire - 1 week ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executi...

Business Wire - 1 month ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the opening for patient screening and enrollment of the...

Business Wire - 1 month ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced achievement of fifty percent enrollment in the IMerge P...

Business Wire - 1 month ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that four oral presentations and six poster presentatio...

Business Wire - 2 months ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 80,000 shares of Geron common...

Seeking Alpha - 2 months ago

Geron Corporation (GERN) John Scarlett Presents at 2020 Stifel Virtual Healthcare Conference (Transcript)

Business Wire - 2 months ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A. Scarlett, M.D., Chairman and Chief Executi...

Seeking Alpha - 2 months ago

Geron Corp (GERN) CEO John Scarlett on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

Geron (GERN) delivered earnings and revenue surprises of -20.00% and 44.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 2 months ago

Shares of Geron (NASDAQ:GERN) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share increased 25.00% over the past year to ($0.06), which were in line...

Business Wire - 2 months ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that ten abstracts containing clinical data and analyse...

Business Wire - 2 months ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today announced that it will release its third quarter 2020 financial results after the market closes on Thursday, Novemb...

Business Wire - 2 months ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that data from the IMerge Phase 2 trial were published ...

Zacks Investment Research - 2 months ago

Geron (GERN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Business Wire - 3 months ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it has entered into a loan facility for up to $75 ...

Other stocks mentioned: HTGC
Zacks Investment Research - 4 months ago

Geron (GERN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Business Wire - 4 months ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 80,000 shares of Geron common...

Seeking Alpha - 4 months ago

Geron Corporation (GERN) CEO John Scarlett Presents at H.C. Wainwright Global Investment Conference Transcript

Business Wire - 4 months ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A.

Business Wire - 5 months ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 270,000 shares of Geron common...

Seeking Alpha - 5 months ago

Geron Corp (GERN) CEO John Scarlett on Q2 2020 Results - Earnings Call Transcript

Business Wire - 5 months ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported financial results for the second quarter ended June 30, ...

Business Wire - 5 months ago

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that John A.

Business Wire - 5 months ago

MENLO PARK, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN) today announced that it will release its second quarter 2020 financial results after the market closes on Thursday, August...

Zacks Investment Research - 5 months ago

Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 5 months ago

Geron has been struggling lately, but the selling pressure may be coming to an end soon

Zacks Investment Research - 6 months ago

Is (GERN) Outperforming Other Medical Stocks This Year?

GlobeNewsWire - 6 months ago

MENLO PARK, Calif., July 01, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that the European Medicines Agency (E...

Zacks Investment Research - 6 months ago

As of late, it has definitely been a great time to be an investor in Geron.

Zacks Investment Research - 7 months ago

Investors need to pay close attention to Geron Corporation (GERN) stock based on the movements in the options market lately.

GlobeNewsWire - 7 months ago

MENLO PARK, Calif., June 12, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that an oral presentation and three p...

Zacks Investment Research - 7 months ago

Geron Corporation (GERN) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.

Zacks Investment Research - 7 months ago

Top Ranked Momentum Stocks to Buy for June 9th

Other stocks mentioned: EBAY, KOPN, RH
Zacks Investment Research - 7 months ago

Geron Corporation (GERN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 7 months ago

Is (GERN) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 7 months ago

Top Ranked Momentum Stocks to Buy for June 5th

Other stocks mentioned: AXU, CODX, RH
Zacks Investment Research - 7 months ago

Top Ranked Momentum Stocks to Buy for June 2nd

Other stocks mentioned: AT, AXU, GSV
Seeking Alpha - 7 months ago

Geron Corp (GERN) CEO John Scarlett on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 7 months ago

Geron (GERN) delivered earnings and revenue surprises of 11.11% and -52.73%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 7 months ago

MENLO PARK, Calif., May 28, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the first quarter ended March 31, 2020. The Company will host a con...

GlobeNewsWire - 7 months ago

MENLO PARK, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the closing of its previously announce...

Market Watch - 8 months ago

Shares of Geron Corp. GERN, +3.70% plunged 26% in premarket trading Friday, after the biopharmaceutical company's large public offering of stock priced at a 34% discount.

GlobeNewsWire - 8 months ago

MENLO PARK, Calif., May 22, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the pricing of its previously announce...

GlobeNewsWire - 8 months ago

MENLO PARK, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it intends to offer and sell shar...

GlobeNewsWire - 8 months ago

MENLO PARK, Calif., May 21, 2020 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced plans for a Phase 3 clinical trial in ...

The Motley Fool - 8 months ago

The bio pharmaceutical announced fresh data on imetelstat that it will present at a key conference next month.

Zacks Investment Research - 8 months ago

Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

InvestorPlace - 9 months ago

There could be a reason penny stocks trade for under $5, but the returns can be monstrous if there's even minor share price appreciation.

Other stocks mentioned: EVRI, MNLO, ORBC, PLUG, RMTI, SELB
The Motley Fool - 9 months ago

In this David versus Goliath battle, which biotech offers investors a greater return?

Other stocks mentioned: XLRN

About GERN

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. It holds rights to imetelstat, a telomerase inhibitor in Phase 2/3 clinical trials, which inhibits the uncontrolled proliferation of malignant progenitor cells in hematologic myeloid malignancies to reduce dysfunctional blood cell production and enable recovery of normal blood cell production. The company was founded in 1990 and is headquartered in Menlo Park, California.

Industry
Biotechnology
IPO Date
Jun 30, 1996
CEO
John Scarlett
Employees
45
Stock Exchange
NASDAQ
Ticker Symbol
GERN
Full Company Profile

Financial Performance

In 2019, Geron's revenue was $460,000, a decrease of -56.85% compared to the previous year's $1.07 million. Losses were -$68.55 million, 153.7% more than in 2018.

Financial Statements

Analyst Forecasts

According to 6 analysts, the average rating for Geron stock is "Strong Buy." The 12-month stock price forecast is 4.00, which is an increase of 131.21% from the latest price.

Price Target
$4.00
(131.21% upside)
Analyst Consensus: Strong Buy